Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Withdrawn × 3-Iodobenzylguanidine × Clear all

Phase

Phase 2 2 Phase 1/2 1 Phase 1 1

Status

Completed 7 Withdrawn 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1 CNS 1

Conditions

Pheochromocytoma 1 Paraganglioma 1 Neuroendocrine Tumors 1

Interventions

Cyclophosphamide 34 Cisplatin 23 Radiotherapy 22 fludarabine 21 Paclitaxel 21 Carboplatin 19 pembrolizumab 18 Nivolumab 18 Magnetic Resonance Spectroscopy 18 Specimen Handling 16 fludarabine phosphate 15 Gemcitabine 15 Biopsy 14 Cytarabine 12 Radiation 11 Filgrastim 11 Doxorubicin 11 Docetaxel 11 Dexamethasone 11 Radiosurgery 10 Melphalan 9 Ipilimumab 9 Granulocyte Colony-Stimulating Factor 9 Etoposide 9 venetoclax 8 Rituximab 8 Calcium Dobesilate 8 trametinib 7 ibrutinib 7 durvalumab 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01941849 2015-12-21

VIBRaNT

University College, London

Phase 1 Withdrawn

CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡